Castle Biosciences
CSTL
153 hedge funds and large institutions have $515M invested in Castle Biosciences in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 55 increasing their positions, 45 reducing their positions, and 18 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
106% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 18
85% more call options, than puts
Call options by funds: $148K | Put options by funds: $80K
31% more capital inflows, than outflows
Capital inflows: $55.9M | Capital outflows: $42.5M
22% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 45
13% more funds holding
Funds holding: 135 → 153 (+18)
2.4% more ownership
Funds ownership: 86.35% → 88.76% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Portolan Capital Management
Boston,
Massachusetts
|
+$8.37M |
| 2 |
Morgan Stanley
New York
|
+$7.73M |
| 3 |
Next Century Growth Investors
Plymouth,
Minnesota
|
+$3.76M |
| 4 |
Intrinsic Edge Capital Management
Chicago,
Illinois
|
+$2.99M |
| 5 |
BlackRock
New York
|
+$2.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GW&K Investment Management
Boston,
Massachusetts
|
-$8.69M |
| 2 |
Granahan Investment Management
Waltham,
Massachusetts
|
-$5.65M |
| 3 |
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.53M |
| 4 |
Wasatch Advisors
Salt Lake City,
Utah
|
-$3.34M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.33M |
CSTL Hedge Fund Activity: Q4 2023 in Review
153 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q4 2023, worth a combined $515M — up 32% from $391M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new CSTL positions and 18 closed out — a net gain of 19 holders — while 55 added to existing stakes and 45 trimmed.
The largest buyer was Portolan Capital Management, adding an estimated $8.37M. The largest seller was GW&K Investment Management, cutting an estimated $8.69M.
- 153 institutional investors held Castle Biosciences (CSTL) as of Q4 2023, up from 135 in Q3 2023.
- Funds reported $515M of Castle Biosciences stock for Q4 2023, up 32% quarter-over-quarter.
- 37 funds opened new Castle Biosciences positions in Q4 2023 and 18 closed out, a net change of +19 holders.
- The largest Castle Biosciences buyer in Q4 2023 was Portolan Capital Management, an estimated $8.37M added.
- The largest Castle Biosciences seller in Q4 2023 was GW&K Investment Management, an estimated $8.69M sold.
Based on aggregated 13F filings for Q4 2023.